ESMO 2021 | Areas of unmet need in mUC

Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, provides an overview of the areas of unmet need for patients with metastatic urothelial carcinoma (mUC), including a better understanding of how to use novel agents in earlier settings, improving treatment combinations as well as identifying biomarkers for response to immunotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.